Published in J Clin Oncol on June 01, 2004
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet (2014) 11.01
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85
Overdiagnosis and overtreatment of prostate cancer. Eur Urol (2014) 3.25
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
MRI-Compatible Pneumatic Robot for Transperineal Prostate Needle Placement. IEEE ASME Trans Mechatron (2008) 2.67
Prostate cancer screening and the management of clinically localized disease. BMJ (2013) 2.45
Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate (2010) 2.40
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst (2013) 2.20
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol (2008) 1.93
Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol (2007) 1.79
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol (2008) 1.68
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol (2012) 1.65
A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer (2006) 1.65
Quality of life in men undergoing active surveillance for localized prostate cancer. J Natl Cancer Inst Monogr (2012) 1.49
Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int (2011) 1.26
Prediction of Gleason score upgrading in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate biopsy. World J Urol (2008) 1.23
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol (2007) 1.10
What is low-risk prostate cancer and what is its natural history? World J Urol (2008) 1.09
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes (2010) 1.09
Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006. Br J Cancer (2009) 1.01
Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol (2012) 1.01
Using biopsy to detect prostate cancer. Rev Urol (2008) 1.00
Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology (2009) 1.00
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta (2012) 0.98
Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med (2007) 0.98
Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2011) 0.97
Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol (2010) 0.96
Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol (2014) 0.94
Brachytherapy with permanent seed implantation. Int J Clin Oncol (2007) 0.94
The example of CaPSURE: lessons learned from a national disease registry. World J Urol (2011) 0.92
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJU Int (2011) 0.92
Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation. Insights Imaging (2015) 0.91
The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. MAGMA (2008) 0.90
Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res (2009) 0.90
Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol (R Coll Radiol) (2013) 0.89
Increasing use of observation among men at low risk for prostate cancer mortality. J Urol (2014) 0.88
Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis (2011) 0.86
Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness. NMR Biomed (2011) 0.86
Focal cryosurgical ablation of the prostate: a single institute's perspective. BMC Urol (2013) 0.85
Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. Int J Radiat Oncol Biol Phys (2005) 0.85
The impact of technology diffusion on treatment for prostate cancer. Med Care (2013) 0.85
Differentiation of prostate cancer cells using flexible fluorescent polymers. Anal Chem (2011) 0.85
A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol (2013) 0.84
Outcomes assessment in men undergoing open retropubic radical prostatectomy, laparoscopic radical prostatectomy, and robotic-assisted radical prostatectomy. World J Urol (2011) 0.84
Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol (2009) 0.83
Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol (2008) 0.83
Focal treatment of prostate cancer with vascular-targeted photodynamic therapy. ScientificWorldJournal (2008) 0.82
Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy. Cancer (2015) 0.82
Appropriateness of Prostate Cancer Imaging among Veterans in a Delivery System without Incentives for Overutilization. Health Serv Res (2015) 0.82
Prostate cancer: Time for active surveillance of intermediate-risk disease? Nat Rev Urol (2012) 0.81
The pathogenesis of prostate cancer: from molecular to metabolic alterations. Diagn Histopathol (Oxf) (2008) 0.81
Do our patients have enough to eat?: Food insecurity among urban low-income cancer patients. J Health Care Poor Underserved (2014) 0.81
The importance of combined radiation and endocrine therapy in locally advanced prostate cancer. Asian J Androl (2011) 0.81
Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int J Radiat Biol (2010) 0.80
Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database. Cancer Causes Control (2013) 0.80
Can erectile function be predicted after prostate cancer treatment? Asian J Androl (2011) 0.80
Managing bone loss and bone metastases in prostate cancer patients: a focus on bisphosphonate therapy. Rev Urol (2008) 0.80
Are histopathological features of prostate cancer lesions associated with identification of extracapsular extension on magnetic resonance imaging? BJU Int (2010) 0.79
Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy (2011) 0.79
Prostate cancer survivorship: lessons from caring for the uninsured. Urol Oncol (2011) 0.78
Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging. Clinics (Sao Paulo) (2011) 0.78
A hospital-based study of initial observation for low-risk prostate cancer and its predictors in the United States. Can Urol Assoc J (2015) 0.78
New techniques and management options for localized prostate cancer. Rev Urol (2006) 0.78
Which better predicts mortality among older men, a prostate cancer (PCa) diagnosis or vulnerability on the Vulnerable Elders Survey (VES-13)? A retrospective cohort study. J Geriatr Oncol (2016) 0.77
Robotic prostate biopsy and its relevance to focal therapy of prostate cancer. Nat Rev Urol (2011) 0.77
Focal therapy for prostate cancer. Rev Urol (2008) 0.77
Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme. Br J Cancer (2015) 0.77
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics (Basel) (2016) 0.77
Genetically adjusted prostate-specific antigen values may prevent delayed biopsies in African-American men. BJU Int (2014) 0.77
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol (2015) 0.77
Focal therapy, differential therapy, and radiation treatment for prostate cancer. Adv Urol (2012) 0.77
Guideline of Guidelines: Imaging of Localized Prostate Cancer. BJU Int (2015) 0.76
Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer. J Clin Imaging Sci (2016) 0.76
Controversies on individualized prostate cancer care: gaps in current practice. Ther Adv Urol (2013) 0.76
The impact of prostate cancer and hormonal therapy on bone. Rev Urol (2009) 0.76
Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy. World J Urol (2008) 0.76
A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. Cancer Epidemiol Biomarkers Prev (2015) 0.76
A New CT Prostate Segmentation for CT-Based HDR Brachytherapy. Proc SPIE Int Soc Opt Eng (2015) 0.76
Early channel transurethral resection of the prostate for patients with urinary retention after brachytherapy. J Zhejiang Univ Sci B (2014) 0.75
Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk. Int J Clin Exp Med (2015) 0.75
Metastasis as a therapeutic target in prostate cancer: a conceptual framework. Am J Clin Exp Urol (2014) 0.75
Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy. Med Phys (2014) 0.75
Minimally invasive ablative therapies for definitive treatment of localized prostate cancer in the primary setting. Prostate Cancer (2010) 0.75
Focal low-dose rate brachytherapy for the treatment of prostate cancer. Cancer Manag Res (2013) 0.75
The biochemical efficacy of primary cryoablation combined with prolonged total androgen suppression compared with radiotherapy on high-risk prostate cancer: a 3-year pilot study. Asian J Androl (2010) 0.75
Development and Phantom Validation of a 3D-Ultrasound-Guided System for Targeting MRI-visible Lesions during Transrectal Prostate Biopsy. IEEE Trans Biomed Eng (2016) 0.75
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology (1996) 3.26
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol (1997) 2.75
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol (2002) 2.53
Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology (2000) 2.15
Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst (2001) 2.09
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer (2002) 1.83
Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ (1998) 1.77
Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol (2003) 1.70
Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology (2002) 1.67
Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int (2002) 1.53
Prostate cancer mortality in patients surviving more than 10 years after diagnosis. J Urol (1995) 1.51
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys (2000) 1.40
High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. Am J Med (1998) 1.32
Is there age bias in the treatment of localized prostate carcinoma? Cancer (2004) 1.29
Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int (2000) 1.21
Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol (2000) 1.19
Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol (2000) 1.19
Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol (2002) 1.08
Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology (2001) 1.06
Long-Term Combined Androgen Blockade Alone for Localized Prostate Cancer. Mol Urol (1999) 0.98
Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group. Jpn J Clin Oncol (2000) 0.98
An analysis of watchful waiting for clinically localized prostate cancer. J Urol (1998) 0.95
Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment? Urology (1995) 0.89
Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol (1999) 0.89
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. Oncologist (2001) 0.87
Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. J Urol (1999) 0.84
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg (2003) 7.95
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22
National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol (2003) 4.11
Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
The changing face of prostate cancer. J Clin Oncol (2005) 3.84
Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84
Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
Population-based comparative effectiveness of nephron-sparing surgery vs ablation for small renal masses. BJU Int (2012) 2.81
The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol (2012) 2.55
Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer. J Urol (2007) 2.39
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med (2006) 2.04
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer (2006) 2.04
Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst (2005) 2.03
Imaging of retained surgical sponges in the abdomen and pelvis. AJR Am J Roentgenol (2003) 2.02
What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol (2008) 2.02
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Increased risk of high-grade prostate cancer among infertile men. Cancer (2010) 2.00
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol (2007) 1.91
Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology (2002) 1.90
Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med (2003) 1.89
Urology resident publication output and its relationship to future academic achievement. J Urol (2010) 1.85
High-risk prostate cancer in the United States, 1990-2007. World J Urol (2008) 1.83
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol (2004) 1.80
Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol (2006) 1.77
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol (2012) 1.75
Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol (2007) 1.70
Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol (2010) 1.70
Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology (2004) 1.69
Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer (2007) 1.68
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68
How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int (2013) 1.61
Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A (2008) 1.61
Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology (2013) 1.59
Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology (2004) 1.58
The quantitative Gleason score improves prostate cancer risk assessment. Cancer (2012) 1.57
Cumulative cost pattern comparison of prostate cancer treatments. Cancer (2007) 1.57
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol (2012) 1.56
Evolving practice patterns for the management of small renal masses in the USA. BJU Int (2012) 1.55
Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol (2013) 1.55
Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol (2002) 1.54
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol (2005) 1.54
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52